These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 13857100)
1. [PHARMACEUTICAL economics and problems]. Gaz Med Fr; 1959 Sep; 66():1349-50. PubMed ID: 13857100 [No Abstract] [Full Text] [Related]
2. Comment on "The economics of follow-on drug research and development: trends in entry rates and the timing of development". Hollis A Pharmacoeconomics; 2005; 23(12):1187-92; discussion 1193-202. PubMed ID: 16336012 [No Abstract] [Full Text] [Related]
3. Drug development means economics in the end. Senn S BMJ; 2001 Mar; 322(7287):675. PubMed ID: 11291652 [No Abstract] [Full Text] [Related]
4. The economics of contraceptives R&D. Djerassi C Science; 1996 Jun; 272(5270):1858-9. PubMed ID: 8658149 [No Abstract] [Full Text] [Related]
5. Qualitative factors underlying the successful investment in new ophthalmic pharmaceutical products in the United States. Stewart WC; Chaney PG; Stewart JA; Kruft B; Nelson LA Acta Ophthalmol; 2013 Sep; 91(6):e496-7. PubMed ID: 23834660 [No Abstract] [Full Text] [Related]
6. Industry comment on the 1995 revised Australian pharmacoeconomic guidelines. Grobler MP; Macarounas-Kirchmann K; Pearce GA; Stafford M Pharmacoeconomics; 1996 Apr; 9(4):353-6. PubMed ID: 10160109 [No Abstract] [Full Text] [Related]
7. Guidelines for measuring the costs and consequences of adopting new pharmaceutical products: are they on track? Pausjenssen AM; Detsky AS Med Decis Making; 1998; 18(2 Suppl):S19-22. PubMed ID: 9566463 [No Abstract] [Full Text] [Related]
8. Drug therapy: safety, effectiveness, and economics. Brandys J Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340 [TBL] [Abstract][Full Text] [Related]